Oct. 11 (Bloomberg) -- Shares of the following companies had unusual moves in U.S. trading. Stock symbols are in parentheses, and prices are as of 4 p.m. in New York.
Airgas Inc. (ARG US) advanced 2.8 percent to $69.78, the highest price since at least December 1986. The industrial-gas distributor plans to appeal a court ruling that would allow its next annual meeting to be held in January. Airgas is fighting a $5.5 billion takeover bid by Air Products & Chemicals Inc. (APD US), which may use the ruling to take control of Airgas at the January meeting.
Alexza Pharmaceuticals Inc. (ALXA US) plunged 54 percent to $1.38, the biggest decline since its March 2006 initial public offering. The Mountain View, California-based company said the U.S. Food and Drug Administration rejected its experimental treatment for use against agitation in patients with schizophrenia or bipolar disorder.
American Reprographics Co. (ARP US) declined 17 percent, the most since October 2009, to $6.54. The provider of document-management services lowered its estimate of 2010 earnings excluding certain items to 9 cents a share at most. Analysts forecast 17 cents a share, according to the average estimate in a Bloomberg survey.
BlackRock Inc. (BLK US) increased 1.7 percent to $177.24, the highest price since May 4. The world’s largest asset-management firm’s Taiwan unit expects assets under management to grow 10 percent a year for the next four years, according to Chang Lin-yun, head of the unit.
The firm aims to start an Asian fixed income fund next year, and plans to sell an international equity fund in the first quarter of next year, Chang said.
Citrix Systems Inc. (CTXS US) slumped 6.7 percent to $55.69 for the biggest decline in the S&P 500. Credit Suisse Group AG analyst Philip Winslow said in a note the software maker’s sales were slower in the third quarter than in the second quarter. Credit Suisse expects a sequential decline in Citrix’s XenDesktop bookings and license revenue, he wrote.
DineEquity Inc. (DIN US) rose 4.9 percent to $49.02, the highest price since May 2008. The restaurant company said it will sell 20 of its Applebee’s Neighborhood Grill & Bar restaurants located in the Roanoke and Lynchburg markets of Virginia to Apple Investors Group LLC.
Gymboree Corp. (GYMB US) surged 22 percent, the most since April 2009, to $64.83. The children’s apparel retailer has agreed to be acquired by Bain Capital LLC for $65.40 a share in cash, or $1.8 billion.
ImmunoGen Inc. (IMGN US) rose 4.8 percent to $7.44, the highest price since Aug. 26. The maker of anticancer drugs said Novartis AG will pay it a $45 million fee for exclusive rights to its technology that uses antibodies to deliver cancer drugs against specific tumor types. ImmunoGen may receive more than $200 million for each cancer drug that results from the agreement, the company said in a statement.
Obagi Medical Products Inc. (OMPI US) slipped 5.9 percent, the most since Aug. 6, to $10.50. The maker of physician-dispensed skin-care treatments said Chief Executive Officer Steven Carlson resigned, effective immediately. Albert Hummel, a director at the company, will take over on an interim basis.
SandRidge Energy Inc. (SD US) fell 4 percent to $5.47, the lowest price since Sept. 28. Chief Executive Officer Tom Ward sold 6 million shares last week, according to a filing Oct. 8.
Sherwin-Williams Co. (SHW US) declined 2 percent, the most since Aug. 19, to $72.04. The largest U.S. paint retailer was cut to “equalweight” from “overweight” at Stephens Group Inc. The price estimate was cut to $78 from $80.
Venoco Inc. (VQ US) slumped 13 percent, the most since January 2009, to $17. The oil and gas producer will get “lower production” in the Sacramento Basin than forecast for 2010, Chief Executive Officer Tim Marquez said in a statement today. Venoco cut its expense guidance to offset a 3 percent reduction in forecast production for the year.
Warner Chilcott Plc (WCRX US) jumped 7.2 percent, the most since June 10, to $23.88. The pharmaceutical company focused on women’s health care announced the U.S. Food and Drug Administration approved its next generation Actonel for the treatment of osteoporosis.
To contact the reporter on this story: Whitney Kisling in New York at email@example.com.
To contact the editor responsible for this story: Nick Baker at firstname.lastname@example.org.